Compare GAIA & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | BEAT |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Movies/Entertainment | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.9M | 54.2M |
| IPO Year | 1999 | N/A |
| Metric | GAIA | BEAT |
|---|---|---|
| Price | $3.11 | $1.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $9.00 | $6.75 |
| AVG Volume (30 Days) | 66.0K | ★ 776.8K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,500,000.00 | N/A |
| Revenue This Year | $13.15 | N/A |
| Revenue Next Year | $16.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.50 | N/A |
| 52 Week Low | $2.93 | $0.54 |
| 52 Week High | $6.39 | $4.00 |
| Indicator | GAIA | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 43.03 |
| Support Level | $2.95 | $1.33 |
| Resistance Level | $4.23 | $1.81 |
| Average True Range (ATR) | 0.22 | 0.12 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 23.08 | 9.80 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.